We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
-1.42%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$384M
AUM Growth
+$54.9M
Cap. Flow
+$63.3M
Cap. Flow %
16.48%
Top 10 Hldgs %
73.72%
Holding
34
New
13
Increased
12
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$12.5M
2
ZBH icon
Zimmer Biomet
ZBH
+$9.31M
3
ITGR icon
Integer Holdings
ITGR
+$9.1M
4
HMSY
HMS Holdings Corp.
HMSY
+$8.13M
5
ICUI icon
ICU Medical
ICUI
+$6.97M

Top Sells

Rank Stock Value
1
HAE icon
Haemonetics
HAE
+$12.1M
2
NVCR icon
NovoCure
NVCR
+$9.64M
3
SRCL
Stericycle Inc
SRCL
+$5.82M
4
MDT icon
Medtronic
MDT
+$2.09M
5
DGX icon
Quest Diagnostics
DGX
+$1.43M

Sector Composition

Rank Sector Weight
1 Healthcare 92.8%
2 Industrials 6.67%
3 Miscellaneous 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDRX
1
DELISTED
Veradigm Inc. Common Stock
MDRX
$46.4M 12.09%
4,225,000
+300,000
+8% +$3.08M
MDT icon
2
Medtronic
MDT
$120B
$43.4M 11.32%
400,000
-20,000
-5% -$2.09M
BIO icon
3
Bio-Rad Laboratories Class A
BIO
$10.3B
$38.3M 9.97%
115,000
+15,000
+15% +$4.89M
PCRX icon
4
Pacira BioSciences
PCRX
$1.05B
$29.5M 7.69%
775,000
+150,000
+24% +$5.99M
PTLA
5
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$26.8M 6.99%
1,000,000
+445,000
+80% +$12.5M
ZBH icon
6
Zimmer Biomet
ZBH
$18.7B
$22M 5.72%
164,800
+72,100
+78% +$9.31M
ATRC icon
7
AtriCure
ATRC
$2.62B
$21.2M 5.52%
850,000
+175,000
+26% +$5M
LNTH icon
8
Lantheus
LNTH
$6.59B
$18.8M 4.9%
750,000
+20,000
+3% +$492K
DGX icon
9
Quest Diagnostics
DGX
$26.2B
$18.7M 4.88%
175,000
-13,900
-7% -$1.43M
SRCL
10
DELISTED
Stericycle Inc
SRCL
$17.8M 4.64%
350,000
-125,000
-26% -$5.82M
HOLX
11
DELISTED
Hologic
HOLX
$14.1M 3.68%
280,000
+5,000
+2% +$246K
RIGL icon
12
Rigel Pharmaceuticals
RIGL
$909M
$10.2M 2.67%
547,500
– –
CMD
13
DELISTED
Cantel Medical Corporation
CMD
$10.1M 2.63%
135,000
+20,000
+17% +$1.7M
CORV
14
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$9M 2.35%
4,500,000
+1,150,000
+34% +$2.33M
ITGR icon
15
Integer Holdings
ITGR
$4.3B
$8.69M 2.26%
+115,000
New +$9.1M
HMSY
16
DELISTED
HMS Holdings Corp.
HMSY
$7.75M 2.02%
+225,000
New +$8.13M
UTHR icon
17
United Therapeutics
UTHR
$20.9B
$5.98M 1.56%
+75,000
New +$6.04M
ICUI icon
18
ICU Medical
ICUI
$4.19B
$5.59M 1.46%
+35,000
New +$6.97M
PHR icon
19
Phreesia
PHR
$679M
$4.85M 1.26%
+200,000
New +$5.27M
OPTN
20
DELISTED
OptiNose
OPTN
$4.72M 1.23%
+45,000
New +$4.49M
RDNT icon
21
RadNet
RDNT
$5.8B
$4.67M 1.22%
+325,000
New +$4.73M
NVRO
22
DELISTED
NEVRO CORP.
NVRO
$4.54M 1.18%
52,864
+2,864
+6% +$217K
ISEE
23
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$3.36M 0.88%
3,000,000
– –
GWPH
24
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.88M 0.75%
+25,000
New +$3.79M
STRM
25
DELISTED
Streamline Health Solutions
STRM
$2.28M 0.59%
140,000
– –
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q3 2019 Portfolio in Review

As of Q3 2019, Tamarack Advisers held 34 positions worth $384M, up 17% from $329M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Tamarack Advisers deployed $63.3M of net new capital in Q3 2019, opening 13 new positions and adding to 12 existing holdings. Its largest new stake was Integer Holdings: 115,000 shares worth $8.69M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Industrials and Miscellaneous.

On the sell side, the largest reduction was Stericycle Inc, an estimated $5.82M trimmed.

  • Tamarack Advisers's largest Q3 2019 buy was Integer Holdings: 115,000 shares worth $8.69M.
  • Tamarack Advisers added most to Portola Pharmaceuticals, Inc. in Q3 2019, an estimated $12.5M increase.
  • Tamarack Advisers's biggest Q3 2019 reduction was Stericycle Inc, cutting an estimated $5.82M.
  • Tamarack Advisers fully exited Haemonetics in Q3 2019, selling an estimated $12.1M.
  • Tamarack Advisers's ten largest holdings make up 74% of its $384M portfolio in Q3 2019.
  • Tamarack Advisers opened 13 new positions and closed 3 in Q3 2019.
  • Tamarack Advisers's portfolio value rose 17% quarter-over-quarter to $384M.

Based on Tamarack Advisers's 13F filing for Q3 2019, filed 5 Nov 2019.